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Abstract
Antigen cross-reactivity is an inbuilt feature of the T cell compartment. However, little is known about the flexibility of T cell
recognition in the context of genetically variable pathogens such as HIV-1. In this study, we used a combinatorial library
containing 24 billion octamer peptides to characterize the cross-reactivity profiles of CD8+ T cells specific for the
immunodominant HIV-1 subtype B Nef epitope VY8 (VPLRPMTY) presented by HLA-B*35:01. In conjunction, we examined
naturally occurring antigenic variationswithin the VY8 epitope. Sequence analysis of plasma viral RNA isolated from336 HIV-1-
infected individuals revealed variability at position (P) 3 and P8 of VY8; Phe at P8, but not Val at P3, was identified as an HLA-
B*35:01-associated polymorphism. VY8-specific T cells generated from several different HIV-1-infected patients showedunique
andclonotype-dependentcross-reactivity footprints.Nonetheless, all T cells recognizedboth the indexLeuandmutantVal atP3
equallywell. In contrast, competitive titration assays revealed that theTyr to Phe substitution at P8 reducedT cell recognitionby
50–130 fold despite intact peptide binding to HLA-B*35:01. These findings explain the preferential selection of Phe at the C-
terminus of VY8 inHLA-B*35:01+ individuals and demonstrate that HIV-1 can exploit the limitations of T cell recognition in vivo.
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Introduction
Hypervariable viruses such as HIV-1 can escape from human
leukocyte antigen class I (HLA-I)-restricted CD8+T cell responses by
acquiring viral genomic mutations within or near immunogenic
epitopes. Such immune escape pathways can be extremely repro-
ducible and broadly predictable based on host HLA-I alleles at a
population level [1,2]. Somewhat paradoxically, however, antigen
cross-reactivity is an inbuilt feature of the T cell compartment [3,4].
Indeed, a single autoimmune T cell receptor (TCR) has recently been
shown to recognize more than a million different peptides within a
broad cross-reactivity profile encompassing unrelated amino acid
substitutions [5]. Furthermore, several lines of evidence suggest that
certain CD8+ T cell subsets with the capacity to cross-recognize
naturally occurring viral variants are advantageous for viral control
in vivo [6–11].However, the trueextentofHIV-1-specificTcell cross-
reactivity remains elusive. In the present study, we characterized the
cross-reactivity footprints of HIV-1-specific CD8+ T cells using
combinatorial peptide library (CPL) scanning to cover all possible
amino acid variations at each position of an octamer epitope.
Additionally, we analyzed antigenic variation within the targeted
epitope region of HIV-1 subtype B. Our investigations focused on
CD8+T cell responses specific for the immunodominant HIV-1 Nef
epitope VY8 (VPLRPMTY) presented by HLA-B*35:01 [12,13].
Materials and Methods
Ethics Statement
All study participants provided informed, written consent at the
AIDS Clinical Center, National Center for Global Health and
Medicine, Japan. The study was approved by the Institutional
Review Board of Kumamoto University and National Center for
Global Health and Medicine.
Sequence Analysis of Autologous HIV-1
Treatment-naı¨ve individuals (n = 336) with chronic HIV-1
infection (.90% subtype B) attending the AIDS Clinical Center
(International Medical Center of Japan) were enrolled for
autologous HIV-1 sequence analysis. The median [IQR] plasma
viral load was 95,000 [31,000–350,000] copies/ml; the median
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[IQR] CD4+ T cell count was 242 [64.5–367.5] cells/mm3. We
determined autologous nef sequences from plasma viral RNA
using a previously reported direct sequencing method [13].
Generation and Maintenance of CD8+ T cell Lines and
Clones
The CD8+ T cell clones (19–136, 19–139 and 33-S1) were
established previously [13]. Additional CD8+ T cell lines and
clones were generated by VY8 peptide stimulation of peripheral
blood mononuclear cells (PBMCs) isolated from HLA-B*35:01+
individuals with chronic HIV-1 infection (Pt-100 and Pt-168) with
10 nM of VY8 (VPLRPMTY) peptide. The Institutional Review
Board of the National Center for Global Health and Medicine
approved both taking samples and generating cell lines, and
patients provided the written informed consent. All CD8+ T cell
lines and clones were maintained in RPMI 1640 supplemented
with 10% fetal calf serum, 10 IU recombinant human interleukin
(IL)-2, antibiotics and L-glutamine.
Analysis of TCR-encoding Genes
TCR-encoding genes of CD8+ T cell lines and clones were
obtained by using a SMART PCR cDNA synthesis kit (Clontech)
and analyzed with reference to the ImMunoGeneTics database
(http://imgt.cines.fr) as described previously [14].
T cell Sensitivity Assay
Secretion of cytokines and chemokines by virus-specific CD8+ T
cells in response to specific antigen provides a useful tool for
quantitative assessment of antigen recognition [15,16]. MIP-1b
was used as a functional readout in this study since it is one of the
most sensitive means to assess functional avidity of human CD8+ T
cells as previously described [15–17]. Briefly, 36104 T cells were
mixed with 66104 HLA-B*35:01-expressing C1R cells (C1R-
B3501), either unpulsed or pulsed with cognate peptide across a
range of concentrations. After overnight incubation at 37uC, the
supernatant was harvested and assayed for MIP-1b content by
ELISA as described previously [5,17]. The amount of MIP-1b
released in the absence of the peptide was subtracted as
background. It should be noted that the VY8 peptide titration
experiments of T cell clones 136 and 139 exhibited comparable
results when IFN-c [13] and MIP-1b were used as readouts (data
not shown).
Table 1. TCR b composition of CD8+ T cell lines.
Patient b chain
V gene J gene CDR3 sequence Frequency
Pt-100 BV2*01 BJ2-7*01 CASSGEGNYEQYF 1/31
CASTTDRVYEQYF 1/31
BV3-1*01 BJ2-5*01 CASSTSSVTETQYF 2/31
BJ2-7*01 CASSQDIAGVHEQYF 1/31
BV4-1*01 BJ2-1*01 CASSQTSGSYNEQFF 1/31
BV6-1*01 BJ1-5*01 CASSEASGIYEQYF 1/31
BJ2-7*01 CASSEASGIYEQYF 1/31
BV10-1*01 BJ2-1*01 CASSAAGVEYNEQFF 1/31
BV11-2*01 BJ1-1*01 CASSFDIVNTEAFF 1/31
BJ2-1*01 CASSPDLVDNEQFF 4/31
BJ2-5*01 CASSGAWTGGGETQYF 2/31
BJ2-7*01 CASSLDLVSYEQYF 1/31
CASSLGIGRAYEQYF 1/31
BV12-3*01 BJ1-4*01 CASSLRFATNEKLFF 1/31
BV27*01 BJ2-5*01 CASSFDTNQETQYF 1/31
BJ2-7*01 CASSLDTNGYEQYF 1/31
CASSFQLAGVHGQYF 1/31
CASSPRLDDEQYF 2/31
CASSLDTSGYEQYF 2/31
CASSSDREDSHEQYF 2/31
BV28*01 BJ2-2*01 CASSSTDRAIPNTGELFF 1/31
BJ2-3*01 CASSLPGLDSTDTQYF 1/31
BJ2-7*01 CASSEGQGRYEQYF 1/31
Pt-168 BV2*01 BJ2-7*01 CASSESLAGGPYEQYF 7/31
BV3-1*01 BJ2-3*01 CASSQEGADTQYF 2/31
BV3-1*02 BJ2-3*01 CASSQEGAGTQYF 1/31
BV6-2*01 BJ1-1*01 CASSGGRTDENTEAFF 1/31
BJ2-1*01 CASSYEREDSGNEQFF 1/31
BV11-2*01 BJ2-7*01 CASSLDVAGSYEQYF 1/31
CASSLDIVSYEQYF 1/31
BV11-3*03 BJ2-3*01 CASSLVLGTGTDTQYF 1/31
BV12-3*01 BJ2-3*01 CASSWDSISTDTQYF 1/31
BJ2-7*01 CASSSDGYEQYF 3/31
BV12-5*01 BJ2-2*01 CASGLAMVVSGELFF 1/31
BV15*02 BJ2-1*01 CATSRDLVEDEQFF 2/31
BV20-1*05 BJ2-2*01 CSARDPRTDRGNTGELFF 1/31
BV24-1*01 BJ2-3*01 CATSVRDDLTGNGPDTQYF 2/31
BV27*01 BJ2-3*01 CASSLDLRPDTQYF 1/31
BV28*01 BJ2-5*01 CASSLLGEETRETQYF 4/31
BV30*01 BJ2-5*01 CAWHTVRVQETQYF 1/31
doi:10.1371/journal.pone.0066152.t001
Table 2. TCR b composition of CD8+ T cell clones.
Patient Clone b chain
V gene J gene CDR3 sequence
Pt-19 19-136 BV7-2*03 BJ2-1*01 CASSPTPQGDYEQFF
19-139 BV11-2*01 BJ1-1*01 CASSLDLVSTEAFF
Pt-33 33-S1 BV4-2*01 BJ2-3*01 CASSQAADAAITDADTQYF
Pt-100 100-K51 BV27*01 BJ2-5*01 CASSFDTNQETQYF
100-K105BV11-2*01 BJ1-1*01 CASSFDIVNTEAFF
100-K810BV27*01 BJ2-7*01 CASSFQLAGVHGQYF
doi:10.1371/journal.pone.0066152.t002
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Octamer Combinatorial Peptide Library (CPL) Scan
The octamer CPL contained a total of 2.461010 different
peptides (PepScan) divided into 160 sub-mixtures in positional
scanning format as described previously [4,18]. Target C1R-
B3501 cells (66104 cells/well) were pre-incubated in the absence
or presence of CPL sub-mixtures (100 mg/ml). Effector T cells (3 x
104 cells/well) were then added and incubated overnight at 37uC.
Supernatant was collected and analyzed for MIP-1b content by
ELISA as described previously [5,17]. Background-subtracted
results were expressed as % response, normalized with respect to
the VY8 index residue. A response .20% was considered positive.
Results and Discussion
Clonotypic Characterization of VY8-specific T cells
CD8+ T cell lines were established from two HLA-B*35:01+
individuals with chronic HIV-1 infection (Pt-100 and Pt-168).
Analysis of TCR b usage by these T cell lines revealed multiple
clonotypes, with 23 and 17 distinct TCR b sequences for Pt-100
and Pt-168, respectively (Table 1). This observation is consistent
with previous studies showing the oligoclonal nature of immuno-
dominant HIV-1-specific CD8+ T cell populations [19,20]. The
CD8+ T cell clones K51, K105 and K810 were generated from
patient Pt-100 by limiting dilution of VY8-specific T cell lines.
Monoclonality was confirmed by TCR b analysis and all three
sequences were encompassed within the TCR repertoire of the
parental T cell lines (Table 2). Additional CD8+ T cell clones (136,
139, and S1) previously established from two separate HLA-
B*35:01+ HIV-1-infected individuals [12,13] showed distinct TCR
b chain usage (Table 2) and were also used for cross-reactivity
studies.
Figure 1. Amino acid residues preferentially recognized by VY8-specific CD8+ T cells. Graphical representation showing relative
preference for amino acid residues recognized by VY8-specific T cell lines and clones based on the CPL scan data shown in Figure S1. Responses
.20% were included. A web-based application, WebLogo 3 (http://weblogo.threeplusone.com/), was used to generate the graphic. Colours
represent physicochemical properties: polar (G, S, T, Y and C), green; neutral (Q and N), purple; basic (K, R and H), blue; acidic (D and E), red;
hydrophobic (A, V, L, I, P, W, F and M), black. The index residues at each position are outlined in yellow. Residue size is proportional to T cell
recognition preference.
doi:10.1371/journal.pone.0066152.g001
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Cross-reactivity Analysis of VY8-specific T cells
The cross-reactivity profiles of VY8-specific T cell lines and
clones were analyzed using a CPL containing a total of 2.461010
different octamer peptides, which allowed qualitative mapping of
preferred T cell recognition residues at each position along the
peptide backbone [4,18]. Different VY8-specific T cell lines and
clones preferentially recognized different amino acid residues
across the octamer peptide backbone (Figure S1). We employed a
graphical representation of these preferential recognition residues
by the VY8-specific T cells (Figure 1). Despite these unique cross-
reactivity patterns, all T cells tested recognized the index VY8
residues efficiently (Figure 1). This finding contrasts with previous
observations using tumor-specific and autoreactive T cell clones
[5,21–23], which typically prefer non-index amino acid residues.
Across all clones, more stringent recognition was observed at
position 2 (P2) and P8 (Figure 1). This most likely reflects the
anchor role of these positions in peptide binding to HLA-B*35:01
[12,24]. The VY8-specific T cell clones, K51, K105 and K810,
showed inherently unique cross-reactivity footprints but less
flexible cross-recognition compared to the parental T cell line
(Figure 1), suggesting increased coverage of viral antigenic
variation through polyclonal TCR cross-reactivity.
Naturally Occurring Antigenic variations within the VY8
Epitope
To investigate the correlation between T cell cross-reactivity
and naturally occurring antigenic variation, we analyzed sequence
polymorphisms within the VY8 epitope. Despite the remarkable
variability of HIV-1 Nef, VY8 is highly conserved, most likely due
to its location partially within a Src homology 3 binding motif that
Figure 2. Naturally arising antigenic variations in the VY8 epitope. (A) Graphical representation showing the frequency of amino acid
residues within the VY8 epitope in subtype B Nef sequences retrieved from the Los Alamos database (n = 1191). WebLogo 3 was used to generate the
graphic. (B) The frequency of consensus (subtype B) and variant amino acid residues at each position of the VY8 epitope is shown for autologous
plasma viral sequences derived from a total of 336 HIV-1-infected individuals, segregated according to HLA-B*35:01 status. Statistical analysis was
performed using Fisher’s exact test. n.s., not significant.
doi:10.1371/journal.pone.0066152.g002
Figure 3. VY8-specific CD8+ T cell sensitivity towards peptide variants. The sensitivity of T cell clones towards the VY8, VY8-3V and VY8-8F
peptides was quantified by measuring the amount of MIP-1b secreted in response to antigen stimulation. Data are representative of duplicate assays
and standard deviation from the mean of two replicates is shown.
doi:10.1371/journal.pone.0066152.g003
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is critical for several Nef functions [25], including HLA-I down-
regulation [13,26]. Nevertheless, in the Los Alamos HIV Sequence
database (http://www.hiv.lanl.gov/content/index), some variabil-
ity within HIV-1 subtype B has been reported at P3 Leu and P8
Tyr of the VY8 epitope, with 2.4% and 8.2% of viral clones
showing polymorphisms in these positions, respectively (Figure 2A).
Given that approximately 40% of Nef sequence polymorphisms
are associated with host HLA-I alleles [1], we examined these
particular variants for HLA-I association. Our previous smaller
study of 69 HIV-1-infected patients indicated that Phe at P8 might
be associated with the HLA-B*35:01 allele [13]. To confirm this
association and examine polymorphisms at P3, we recruited a
larger cohort comprising 336 treatment-naı¨ve individuals with
chronic HIV-1 infection and determined autologous nef sequences
from plasma viral RNA. Although we found some variability at P3
(3%), there were no statistically significant amino acid differences
at P1–P7 between individuals with or without HLA-B*35:01
(Figure 2B). In fact, CPL scanning showed that, at P3,
hydrophobic residues including both the index Leu and mutant
Val were preferentially recognized by all VY8-specific T cells
tested (Figure 1). Such flexible TCR recognition at P3 helps to
explain why the Val mutant is not selected in HLA-B*35:01+
individuals. Conversely, we found a statistically significant
difference in the frequency of polymorphisms at P8 between
individuals with or without HLA-B*35:01 (Figure 2B); indeed, the
vast majority (74%) of HLA-B*35:01+ donors harboured viral
sequences with Phe at P8. However, CPL scanning showed that
Phe was a favoured amino acid residue recognized by T cell lines
and some clones, such as K105 (Figure 1 and Figure S1). In these
instances, CPL data alone do not simply explain the emergence of
this viral mutation in HLA-B*35:01+ individuals.
VY8-specific T cell Sensitivity Towards Peptide Variants
To verify the effect of single mutations within the VY8 peptide
on TCR sensitivity, we performed competitive titration assays
across our panel of VY8-specific T cells (Figure 3). Consistent with
the CPL scan data, all T cells tested recognized the VY8 and VY8-
3V peptides comparably (,2 fold difference in EC50 values;
Table 3). In contrast, the EC50 values for VY8-8F were .50 fold
higher than index for all T cells tested (Table 3). These
observations are consistent with previous reports showing that
VY8-specific T cells could not recognize CD4+ T cells or
macrophages infected with HIV-1 carrying this Nef variant at
P8 [13,26].
Although P8 is an anchor residue for VY8, our previous HLA-I
stabilization studies showed comparable binding activity between
HLA-B*35:01 and either VY8 or VY8-8F [13]. The crystal
structure of the VY8/HLA-B*35:01 complex shows that P8 Tyr
lies deep inside the F pocket of the HLA-I molecule [24].
Substitution at this position with the aromatic residue Phe may not
induce substantial structural changes. Consequently, impaired T
cell recognition of P8 Phe may be mediated by indirect
conformational changes imposed by the peptide upon TCR
binding [17]. In the context of HLA-A*02:01, however, a Tyr to
Phe substitution at the secondary anchor P3 of an antigenic
peptide (SLFNTVATL) leads to unexpectedly large conforma-
tional changes in the peptide backbone [27]. Accordingly, further
structural studies are needed to elucidate the precise mechanism
through which anchor residue substitution leads to impaired T cell
recognition of the VY8 epitope.
Previous studies have shown that the double substitution of Arg-
71 to Thr and Tyr-81 to Phe (P8 at VY8) [13], or Pro-75 to Ala
(P2 at VY8) as a single mutation, impair Nef-mediated down-
regulation of HLA-I and thereby increase the susceptibility of
HIV-1-infected cells to killing by CD8+ T cells targeting other
epitopes [26,28]. In contrast, the Tyr-81 to Phe (P8 at VY8)
mutation alone exerts virtually no effect on Nef-mediated activities
[13,26]. Collectively, these data suggest that the P8 Phe mutation
does not compromise viral fitness.
Concluding Remarks
CD8+ T cell responses against the immunominant HIV-1
subtype B-derived Nef epitope VY8 presented by HLA-B*35:01
are highly polyclonal, broadly cross-reactive and capable of
tolerating natural viral variation with one notable exception.
Specifically, the observed Phe substitution at P8, which is neutral
in terms of Nef-mediated function [13,26], was found to reduce
CD8+ T cell recognition by .50 fold. The association of this
mutation with HLA-B*35:01+ strongly suggests that evasion of
VY8-specific CD8+ T cell activity confers a selection advantage
in vivo. Thus, even CD8+ T cell responses with extensive cross-
reactivity profiles can succumb to immune escape at a single
position.
Supporting Information
Figure S1 CPL scanning of VY8-specific CD8+ T cells. The
cross-reactivity profiles of T cell lines and clones specific for VY8
were tested by using 160 CPL sub-mixtures (100 mg/ml) compris-
ing a total of 2.461010 different octamer peptides. In every peptide
mixture, one position has a fixed amino acid residue and all other
positions are degenerate, with the possibility of any one of 19
natural amino acids being incorporated in each individual position
(cysteine is excluded). The amount of MIP-1b secreted in response
to antigen was quantified by ELISA. Data are background-
subtracted and the relative T cell response is shown as a ratio of
MIP-1b production with respect to the index residue at each
position. Responses .20% were considered positive and used to
construct Figure 1. A representative set of duplicate assays is
shown. Red bars depict residues corresponding to the VY8 index
sequence.
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